Sinopharm Group Co. Ltd.

SEHK:1099 Stock Report

Market Cap: HK$57.5b

Sinopharm Group Future Growth

Future criteria checks 1/6

Sinopharm Group is forecast to grow earnings and revenue by 4.5% and 3.9% per annum respectively. EPS is expected to grow by 4.7% per annum. Return on equity is forecast to be 9.7% in 3 years.

Key information

4.5%

Earnings growth rate

4.68%

EPS growth rate

Healthcare earnings growth14.3%
Revenue growth rate3.9%
Future return on equity9.66%
Analyst coverage

Good

Last updated30 Apr 2025

Recent future growth updates

Earnings Miss: Sinopharm Group Co. Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts

Mar 26
Earnings Miss: Sinopharm Group Co. Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts

Recent updates

We Think You Can Look Beyond Sinopharm Group's (HKG:1099) Lackluster Earnings

May 06
We Think You Can Look Beyond Sinopharm Group's (HKG:1099) Lackluster Earnings

Earnings Miss: Sinopharm Group Co. Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts

Mar 26
Earnings Miss: Sinopharm Group Co. Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts

Sinopharm Group (HKG:1099) Is Reinvesting At Lower Rates Of Return

Mar 19
Sinopharm Group (HKG:1099) Is Reinvesting At Lower Rates Of Return

Sinopharm Group Co. Ltd.'s (HKG:1099) Share Price Is Matching Sentiment Around Its Earnings

Feb 25
Sinopharm Group Co. Ltd.'s (HKG:1099) Share Price Is Matching Sentiment Around Its Earnings

Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

Dec 30
Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet

At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?

Nov 26
At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Jul 27
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Jun 16
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Earnings and Revenue Growth Forecasts

SEHK:1099 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027653,5568,55813,98216,19911
12/31/2026641,5788,69212,14610,70117
12/31/2025596,4217,24824,0637,45414
3/31/2025578,9047,08723,16524,752N/A
12/31/2024584,5087,0509,80811,546N/A
9/30/2024590,2678,334-1813,574N/A
6/30/2024590,3468,65316,76819,506N/A
3/31/2024598,3188,8848,03510,385N/A
12/31/2023596,5709,05414,88917,173N/A
9/30/2023591,6868,76519,02721,349N/A
6/30/2023591,6268,9369,66011,931N/A
3/31/2023570,0678,68814,30216,763N/A
12/31/2022552,1488,52618,64820,964N/A
9/30/2022546,1477,91437,50938,425N/A
6/30/2022533,4037,8704922,783N/A
3/31/2022528,3837,9705,3787,658N/A
12/31/2021521,0517,7597,0819,308N/A
9/30/2021510,0917,9304,5116,795N/A
6/30/2021501,7707,8748,74310,983N/A
3/31/2021474,7986,956-12,001-9,890N/A
12/31/2020456,4157,1879,09911,155N/A
9/30/2020440,1946,6155,9988,075N/A
6/30/2020427,3726,1742,3044,522N/A
3/31/2020431,9766,55424,34426,653N/A
12/31/2019425,2736,25116,41718,777N/A
9/30/2019406,3946,311-52,113N/A
6/30/2019382,7176,012-2241,744N/A
3/31/2019360,7606,087-5,010-3,011N/A
12/31/2018344,5265,834N/A3,654N/A
9/30/2018336,1135,523N/A-6,868N/A
6/30/2018334,0605,606N/A2,882N/A
3/31/2018318,4145,083N/A-6,249N/A
12/31/2017308,3545,572N/A3,209N/A
9/30/2017288,8555,217N/A-19N/A
6/30/2017269,3564,861N/A-3,247N/A
3/31/2017264,6914,996N/AN/AN/A
12/31/2016258,3884,635N/A9,258N/A
9/30/2016251,4014,515N/A11,117N/A
6/30/2016244,4144,394N/A12,975N/A
3/31/2016234,4993,885N/AN/AN/A
12/31/2015228,6733,772N/A13,412N/A
9/30/2015222,5133,548N/A9,472N/A
6/30/2015216,3533,323N/A5,533N/A
3/31/2015207,8653,037N/AN/AN/A
12/31/2014200,1312,875N/A5,561N/A
9/30/2014190,8832,719N/A5,747N/A
6/30/2014181,6352,564N/A5,933N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1099's forecast earnings growth (4.5% per year) is above the savings rate (2.4%).

Earnings vs Market: 1099's earnings (4.5% per year) are forecast to grow slower than the Hong Kong market (10.4% per year).

High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1099's revenue (3.9% per year) is forecast to grow slower than the Hong Kong market (8.5% per year).

High Growth Revenue: 1099's revenue (3.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (9.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/14 10:07
End of Day Share Price 2025/05/14 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sinopharm Group Co. Ltd. is covered by 45 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Bo LiBofA Global Research